

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



VaV1 (A168) Peptide

Cat No.: BS3588P

Background

The Vav gene was originally identified on the basis of its oncogenic activation during the course of gene transfer assays. The major translational product of the Vav proto-oncogene has been identified as a protein containing an array of structural motifs. Contained within its amino terminus are a helix-loop-helix domain and a leucine zipper motif similar to that of Myc family proteins; deletion of this region of p95Vav causes its oncogenic activation. In addition, p95Vav contains an SH2 domain, which could indicate its role as a substrate for tyrosine kinases. Expression of p95Vav is limited exclusively to cells of hematopoietic origin, including those of the erythroid, lymphoid and myeloid lineages.

Swiss-Prot

P15498

Applications

Blocking

Specificity

This peptide can be used with studies using BS3588 VaV1 (A168) pAb.

Purification & Purity

Synthetic peptide VaV1 (A168). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.